Tirzepatide 10mg dual GIP GLP-1 agonist Twincretin peptide for research
Tirzepatide 10mg dual agonist research vial label with batch information
Tirzepatide 10mg Certificate of Analysis COA document
Tirzepatide 10mg dual GIP GLP-1 agonist Twincretin peptide for research
Tirzepatide 10mg dual agonist research vial label with batch information
Tirzepatide 10mg Certificate of Analysis COA document

Tirzepatide (GIP/GLP-1 Dual Agonist) 10mg – Lyophilized Peptide

$90.00

Tirzepatide 10mg represents a significant leap in incretin-based metabolic research. Often referred to in scientific literature as a “Twincretin,” this single molecules acts as a dual agonist for both the Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) receptors.

Our 10mg lyophilized preparation provides a highly pure (≥99% HPLC) reagent for investigating the synergistic effects of simultaneous receptor activation on glycemic control, lipid metabolism, and energy homeostasis.

PeptideHub Research Usage∗

In stock

SKU: pw-trz-10 Categories: , ,

Description

What Is Tirzepatide?

Tirzepatide is a synthetic 39-amino-acid dual GIP/GLP-1 receptor agonist (MW: 4,813 Da, CAS: 2023788-19-2). The first dual incretin to activate both GIP and GLP-1 receptors simultaneously. SURMOUNT-1 reported 20.9% mean weight reduction; SURPASS-2 showed superiority over semaglutide. HPLC-verified at 99%+ purity with publicly available COA.

Why Researchers Choose Tirzepatide

  • Dual GIP/GLP-1 receptor agonist — the only “Twincretin” for dual-pathway metabolic research
  • Novel imbalanced agonism mechanism under active investigation in published literature
  • ≥99% purity verified via independent third-party HPLC and mass spectrometry
  • 10mg lyophilized format for precision research into synergistic incretin signaling
  • Key comparator compound alongside Semaglutide and Retatrutide in metabolic research

Frequently Asked Questions

What is Tirzepatide and what research applications does it support?

Tirzepatide is a dual agonist targeting both GIP and GLP-1 receptors simultaneously, often referred to as a “Twincretin.” It is investigated in research protocols examining synergistic effects on glycemic control, lipid metabolism, and energy homeostasis. This compound is sold strictly for laboratory research purposes only.

How do I reconstitute Tirzepatide for laboratory use?

Add 2mL of bacteriostatic water to yield a concentration of 5mg/mL. Follow standard reconstitution research protocols. For detailed instructions, see our Reconstitution 101 guide.

What purity verification does Peptideware provide for Tirzepatide?

Every batch of Tirzepatide undergoes independent third-party HPLC testing confirming ≥99% purity, along with mass spectrometry confirmation. A Certificate of Analysis (COA) is available for each lot.

How should I store Tirzepatide?

In lyophilized form, store at -20°C for long-term storage or 2-8°C for short-term storage. Once reconstituted for research, store at 2-8°C and use within 28 days.

How does Tirzepatide differ from Semaglutide and Retatrutide?

Tirzepatide targets 2 receptors (GIP + GLP-1), Semaglutide targets 1 (GLP-1 only), and Retatrutide targets 3 (GLP-1 + GIP + GCGR). Each compound offers a different receptor activation profile for different metabolic research models.

What published research exists on Tirzepatide?

Published research is available on PubMed covering dual incretin signaling, body composition analysis, and metabolic homeostasis in preclinical research contexts.

Can Tirzepatide be used in comparison research?

Yes. Tirzepatide is a key comparator alongside Semaglutide (single agonist) and Retatrutide (triple agonist) in incretin research protocols. All three compounds are available at Peptideware for comprehensive research.

Further Reading

Mechanism: Dual GIP & GLP-1 Receptor Agonism

Tirzepatide is engineered to function through a unique pharmacological principle known as “Imbalanced Agonism.” Unlike a balanced 1:1 ratio, Tirzepatide exhibits a specific binding affinity bias that is central to its potency:

  • GIP Receptor Bias: It binds with high affinity to the GIP receptor, comparable to native GIP.

  • GLP-1 Receptor Interaction: It binds with lower affinity to the GLP-1 receptor compared to native GLP-1.

The Synergistic Outcome: Research suggests this specific “imbalance” is key to its efficacy. By heavily recruiting the GIP pathway while simultaneously stimulating GLP-1 pathways, Tirzepatide is observed in preclinical models to produce metabolic outcomes—such as reductions in adiposity and improvements in insulin sensitivity—that statistically surpass those of mono-agonists (like Semaglutide) alone.

This research peptide undergoes rigorous quality control and stability testing to ensure maximum integrity for scientific applications. Each batch is manufactured under strict laboratory conditions and verified through independent laboratory analysis.

⚠️ FOR RESEARCH PURPOSES ONLY

This product is strictly for in-vitro laboratory research, analysis, and development. It is not intended for human consumption, injection, or therapeutic use. Tirzepatide is not a drug, dietary supplement, or food. All statements regarding the physiological mechanisms of Tirzepatide are based on preclinical animal and cell-culture studies and are provided for educational and informational purposes only.

hemical Profile: The C20 Modification

Structurally, Tirzepatide is a 39-amino acid linear peptide analogue of the gastric inhibitory polypeptide (GIP).

  • The C20 Fatty Diacid Moiety: The critical structural modification is the attachment of a C20 fatty diacid moiety via a hydrophilic linker.

  • Pharmacokinetic Impact: This fatty acid chain promotes high-affinity binding to plasma albumin. This albumin binding acts as a reservoir, protecting the peptide from enzymatic degradation and renal filtration, resulting in an extended half-life of approximately 5 days (116.5 hours) in research subjects.

Technical Specifications

Specification Detail
Research Code LY3298176
Sequence Length 39 Amino Acids (Linear)
Modification C20 Fatty Diacid Acylation
CAS Number 2023788-19-2
Formula C₂₂₅H₃₄₈N₄₈O₆₈
Molar Mass 4813.45 g/mol
Purity ≥99% (HPLC Verified)

Frequently Bought Together

You may also like…

Legal Disclaimer & Safety Information

This product is sold as a pure research compound exclusively for laboratory research purposes and is not intended for use as a dietary supplement, medication, or for human/animal consumption. These research chemicals have not been evaluated by the U.S. Food and Drug Administration (FDA) and are not pharmaceuticals, medications, or dietary supplements. They have not received FDA approval for the treatment, prevention, diagnosis, mitigation, or cure of any disease, medical condition, or ailment. Keep this product out of the reach of children and unauthorized personnel, as this material may result in adverse effects if improperly handled or consumed. This product is for use and handling only by qualified professionals with the knowledge, training, and equipment to safely handle research chemicals. Under no circumstances should these products be utilized as drugs, agricultural or pesticide products, food additives, or household chemicals, and any form of introduction into the human or animal body is prohibited by law. By making a purchase from Peptideware, you acknowledge that you are acquiring research chemicals exclusively intended for in-vitro laboratory research use by qualified and licensed professionals only. All articles, information, and product descriptions provided on this website are strictly for educational and informational purposes. We attest exclusively to the quality, purity, and description of the materials we provide. Misrepresentation of these products for unauthorized purposes is strictly prohibited by law. You agree to indemnify and hold us harmless for any adverse effects, claims, expenses, losses, and liabilities that may arise from improper handling, misuse, or consumption of this product. Please refer to our terms and conditions prior to purchase.